It is therefore possible that relapses observed in ErbB2-positive breast cancer patients receiving adjuvant Trastuzumab (humanized antibody anti-Her2-Herceptin) or Lapatinib (small tyrosine kinases inhibitor molecule),2, 3 is due to the presence of CSCs that escape these therapeutic agents. The gene discussed is ERBB2; the disease is breast carcinoma.